Galmed Pharmaceuticals (GLMD) Competitors $1.37 -0.08 (-5.52%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.44 +0.07 (+5.11%) As of 08/7/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. IMCC, RNAZ, ACXP, DWTX, XFOR, APRE, SNGX, SONN, CHRO, and ADXNShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include IM Cannabis (IMCC), TransCode Therapeutics (RNAZ), Acurx Pharmaceuticals (ACXP), Dogwood Therapeutics (DWTX), X4 Pharmaceuticals (XFOR), Aprea Therapeutics (APRE), Soligenix (SNGX), Sonnet BioTherapeutics (SONN), Chromocell Therapeutics (CHRO), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors IM Cannabis TransCode Therapeutics Acurx Pharmaceuticals Dogwood Therapeutics X4 Pharmaceuticals Aprea Therapeutics Soligenix Sonnet BioTherapeutics Chromocell Therapeutics Addex Therapeutics Galmed Pharmaceuticals (NASDAQ:GLMD) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Do analysts recommend GLMD or IMCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, GLMD or IMCC? Galmed Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Do institutionals and insiders have more ownership in GLMD or IMCC? 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is GLMD or IMCC more profitable? Galmed Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -9.10%. Galmed Pharmaceuticals' return on equity of -32.21% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -32.21% -28.59% IM Cannabis -9.10%-122.96%-11.69% Does the media refer more to GLMD or IMCC? In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Galmed Pharmaceuticals and 1 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.00 beat Galmed Pharmaceuticals' score of -0.81 indicating that IM Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, GLMD or IMCC? Galmed Pharmaceuticals has higher earnings, but lower revenue than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.08IM Cannabis$54.47M0.19-$7.72M-$0.64-4.00 SummaryGalmed Pharmaceuticals beats IM Cannabis on 8 of the 13 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.40M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.17%P/E Ratio-0.0819.6629.8525.14Price / SalesN/A634.78422.3397.16Price / CashN/A165.0335.9458.58Price / Book0.144.198.125.59Net Income-$7.52M$31.61M$3.26B$265.48M7 Day Performance-11.61%0.95%0.68%1.22%1 Month Performance-34.45%2.90%2.46%0.39%1 Year Performance-59.23%4.11%27.99%23.47% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals0.6345 of 5 stars$1.37-5.5%N/A-59.9%$2.40MN/A-0.0820Short Interest ↑Gap DownIMCCIM Cannabis0.2508 of 5 stars$2.63+4.0%N/A-16.3%$10.23M$54.47M-4.11340Upcoming EarningsGap DownRNAZTransCode Therapeutics1.9611 of 5 stars$11.40-0.9%$280.00+2,356.1%-99.9%$9.59MN/A0.009Upcoming EarningsGap DownACXPAcurx Pharmaceuticals2.1845 of 5 stars$0.29-4.8%$8.00+2,636.0%-88.1%$9.44MN/A-0.423Upcoming EarningsDWTXDogwood Therapeutics1.4452 of 5 stars$4.86+0.2%$10.00+105.8%N/A$9.27MN/A-0.275News CoverageXFORX4 Pharmaceuticals4.4625 of 5 stars$1.58-1.3%$72.33+4,478.1%-92.3%$9.26M$2.56M0.7480APREAprea Therapeutics2.8517 of 5 stars$1.70+2.4%$15.50+811.8%-49.2%$9.18M$1.50M-0.727Upcoming EarningsSNGXSoligenix2.0988 of 5 stars$3.11+13.5%$6.00+92.9%-3.2%$8.94M-$117.03K-0.7220High Trading VolumeSONNSonnet BioTherapeutics2.4945 of 5 stars$2.81flat$20.00+611.7%-51.4%$8.90M$20K0.0010Upcoming EarningsGap UpCHROChromocell TherapeuticsN/A$1.34+6.3%N/A-81.2%$8.69MN/A-1.084Gap UpHigh Trading VolumeADXNAddex Therapeutics2.9052 of 5 stars$8.24+1.7%$30.00+264.3%+5.5%$8.58M$460K-24.2230 Related Companies and Tools Related Companies IMCC Competitors RNAZ Competitors ACXP Competitors DWTX Competitors XFOR Competitors APRE Competitors SNGX Competitors SONN Competitors CHRO Competitors ADXN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
